US EditionAlcon to Acquire LumiThera and Its Dry AMD Light Therapy Device
9 Articles
9 Articles
Ophthalmic laboratory Alcon has agreed to acquire Washington-based medtech company Lumithera, which specializes in devices for diagnosing and managing dry age-related macular degeneration.
ophthalmologytimes.com
Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD
LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.
Alcon to Acquire LumiThera, Maker of Photobiomodulation Device for the Treatment of Dry AMD
In a move to bolster is vitreoretinal surgery portfolio, Alcon announced its intention to acquire LumiThera and its photobiomodulation (PBM) device for the treatment of dry early and intermediate dry AMD. Financial terms of the deal were not disclosed. According to Alcon, LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.[2] The device…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
